Ajanta Pharma Ltd`s Generic Tetrabenazine Receives Approval In US
Health Canada Issues Recall of Sterimax Inc`s Sterimax Tetrabenazine
Piramal Healthcare's Generic Tetrabenazine Receives Approval in U.S
West-Ward Pharms Int`s Generic Tetrabenazine Receives Approval in US
Lupin`s Generic Tetrabenazine Receives Approval In US
Dr Reddys Labs Generic Tetrabenazine Receives Approval In US
Bionpharma’s Generic Tetrabenazine Receives Approval In US
The US FDA has approved its first deuterated drug, clearing Teva’s Austedo (deutetrabenazine) for Huntington’s disease-related movement disorders.
Welcome to your weekly digest of approaching regulatory and clinical readouts. Teva (NYSE:TEVA) expects a US decision on SD-809, its possible treatment for Huntington’s chorea, at the beginning of April. This is the company’s biggest growth driver, though most forecast sales are assigned to its second indication, tardive dyskinesia, for which it will go in front of regulators later this year.
Patients with the movement disorder tardive dyskinesia (TD) could have a first approved treatment if the FDA clears Teva's SD-809 candidate later this year.